Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Cost Savings In Europe Beyond 25% Might Cull Sponsors, EGA Warned

Executive Summary

Trade association hears pricing discipline and differentiated products are keys to sustaining European biosimilars market even as it continues to grow.

Advertisement

Related Content

How US Can Learn From Biosimilar Implementation In EU
European Savings From Small-Molecule Generic Launches Likely To Tail Off
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056916

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel